Viscofan SA (VIS.MC) stock: key figures, P/E, revenue and dividend
Consumer Staples · Spain · ISIN ES0184262212
Viscofan SA financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.20 bn EUR | 1.25 bn EUR |
| Gross profit | 813.00 m EUR | 467.00 m EUR |
| Operating income | 201.32 m EUR | 203.38 m EUR |
| EBIT | 216.00 m EUR | 203.00 m EUR |
| Net income | 157.00 m EUR | 159.00 m EUR |
| Diluted EPS – continuing operations | 3.43 EUR | 3.44 EUR |
Full history since 1996, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Viscofan SA
Viscofan, S.A., together with its subsidiaries, manufactures, produces, and distributes casings in Spain, Rest of Europe, Middle East, Africa, Pacific Asia, North America, South America, and internationally. The company offers cellulose, collagen, fibrous, functional solutions, plastics, viscofan veggie, efan, edileaf, nutra-pharma collinstant, nutra-pharma satiscoll, and medical. It also provides collagen casings for processed and pre-cooked fried sausages, and dry-cured snacks, as well as collagen film cover for meat products under the Total Control Net brand. In addition, it offers fibrous casings under the TITANIUM LINE brand. Viscofan, S.A. was incorporated in 1975 and is based in Tajonar, Spain.
More stocks
- Sankyo Co Ltd (6417.T)
- Alupar Investimento SA (ALUP11.SA)
- CES Energy Solutions Corp (CEU.TO)
- Qinhuangdao Port Co Ltd (601326.SS)
- Knowles Corp (KN)
- TOOTSIE ROLL INDUSTRIES INC (TR)
- Shanghai Bairun Flavor & Fragrance Co Ltd (002568.SZ)
- Joincare Pharmaceutical Group Industry Co Ltd (600380.SS)
- WuHu Foresight Technology Co.,Ltd. (301529.SZ)
- Kangmei Pharmaceutical Co Ltd (600518.SS)
- AXCELIS TECHNOLOGIES INC (ACLS)
- Shanghai Bright Power Semiconductor (688368.SS)
Not investment advice. All data without warranty, price as of 02.11.2026. Details in the risk notice.